Cure­Vac names a US sub­sidiary CEO to ad­vance mR­NA work; Sune­sis shares slide af­ter reg­u­la­tors nix drug app

→ Ger­many’s Cure­Vac has named a US CEO to help ad­vance its work on mR­NA. And not sur­pris­ing­ly he’ll be based in the Boston/Cam­bridge hub, where ri­val Mod­er­na has been at­tract­ing at­ten­tion — of all va­ri­eties. “As CEO of Cure­Vac Inc., my goal will be to ex­pand Cure­Vac’s US busi­ness en­ti­ty and to fo­cus the cor­po­rate de­vel­op­ment ef­forts to grow our busi­ness glob­al­ly,” said Daniel Menichel­la, who’s tak­ing the post.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER